2-Methyltryptamine CAS 2731-06-8 Purity >99.0% (HPLC) Panobinostat Intermediate Factory High Quality

Chemical Name: 2-Methyltryptamine CAS: 2731-06-8 Purity: >99.0% (HPLC) Appearance: Brown Solid  Intermediate of Panobinostat (CAS: 404950-80-7) High Quality, Commercial Production E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Manufacturer Supply With High Quality, Commercial Production  Chemical Name: 2-Methyltryptamine CAS: 2731-06-8
Item Specifications
Appearance Brown Solid 
Purity / Analysis Method >99.0% (HPLC Area)
1-HNMR Consistent With Structure
Loss on Drying <1.00%
Single Impurity <0.50%
Total Impurities <1.00%
Heavy Metals (as Pb) <20ppm
Test Standard Enterprise Standard
Usage Pharmaceutical Intermediates; Panobinostat Intermediate

Description:

Specifications:

Package & Storage:

Chemical Name 2-Methyltryptamine
Synonyms 2-Methylindole-3-Ethylamine; 2-(2-Methyl-1H-indol-3-yl)ethanamine; 3-(2-Aminoethyl)-2-Methylindole
CAS Number 2731-06-8
CAT Number RF-PI1480
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C11H14N2
Molecular Weight 174.25
Melting Point 106.0 to 110.0℃
Boiling Point 177℃/1.5mmHg(lit.)
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

2-Methyltryptamine (CAS: 2731-06-8) is a key starting material in the synthesis of Panobinostat (LBH589) (CAS: 404950-80-7). Panobinostat is a potent inhibitor of all histone deacetylases (HDACs), with Ki values ranging from 0.6 to 31 nM for HDAC1-11. Through this action, it leads to acetylation of a range of cellular proteins, resulting in cell cycle arrest and apoptosis in cancer cells. Panobinostat is the first HDAC inhibitor was approved by FDA for the treatment of multiple myeloma. Panobinostat is marketed as Farydak, is used in combination with Bortezomib (CAS: 179324-69-7) and Dexamethasone (CAS: 50-02-2) to treat relapsed multiple myeloma after prior treatment with Bortezomib and an immunomodulator.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours